Home › Funds › Palo Alto Investors LP › ACAD
Palo Alto Investors LP position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
Palo Alto Investors LP reported holding 2,485,608 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$50.1M, representing 7.45% of its reported portfolio and ranking #4 among its reported holdings. Palo Alto Investors LP has disclosed ACAD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's ACAD position evolved
Palo Alto Investors LP first disclosed a stake in ACAD in Q3 2023 at 2,405,793 shares (US$50.1M). The position peaked in Q4 2023 at 2,409,556 shares, worth US$75.4M. Across 13 filings, Palo Alto Investors LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 2,485,608 shares valued at US$50.1M — a reduction of -378,488 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.41M | $50.14M | New |
| Q4 2023 | 2.41M | $75.44M | Hold |
| Q1 2024 | 2.41M | $44.65M | Hold |
| Q2 2024 | 2.42M | $39.31M | Hold |
| Q3 2024 | 2.52M | $38.82M | Add |
| Q4 2024 | 2.75M | $50.44M | Add |
| Q1 2025 | 2.66M | $44.25M | Reduce |
| Q2 2025 | 2.56M | $55.29M | Reduce |
| Q3 2025 | 2.47M | $52.64M | Reduce |
| Q4 2025 | 2.48M | $66.35M | Add |
| Q1 2026 | 2.87M | $63.95M | Add |
| Q2 2026 | 2.86M | $72.46M | Hold |
| Q3 2026 | 2.49M | $50.09M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$864.7M), RTW INVESTMENTS, LP (US$144.0M), Frazier Life Sciences Management, L.P. (US$29.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- BAKER BROS. ADVISORS LP 42.91M sh · $864.70M · Q3 2026
- RTW INVESTMENTS, LP 7.14M sh · $143.96M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.44M sh · $28.98M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held ACAD?
Palo Alto Investors LP has disclosed ACAD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in ACAD?
As of Q3 2026, Palo Alto Investors LP holds 2.49M shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $50.09M, representing 7.45% of its reported portfolio and ranking #4.
Has Palo Alto Investors LP been buying or selling ACAD?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in ACAD. The position peaked in Q4 2023 at 2.41M shares.
Which other funds hold ACAD?
Other major institutional holders of ACAD include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Frazier Life Sciences Management, L.P., among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.